Skip to content

Dr. Gearóid Tuohy

Ocugen Inc., receives European Medicines Agency (EMA) designation of Advanced Therapy Medicinal Product (ATMP) for “OCU400” to enter for Phase 3 for retinitis pigmentosa. 

Ocugen Inc., (NASDAQ:OCGN), an ophthalmic biopharmaceutical company based in Malvern, Pennsylvania, has announced that the European Commission has provided a positive opinion from the European… Read More »Ocugen Inc., receives European Medicines Agency (EMA) designation of Advanced Therapy Medicinal Product (ATMP) for “OCU400” to enter for Phase 3 for retinitis pigmentosa. 

An analysis of the mutation spectrum for IRDs provides 20 further novel variants, including 6 variants showing pathogenic alterations.

Researchers at the Department of Pathology, University of Oklahoma Health Sciences Centre, USA, have reported a study expanding on the mutation spectrum for inherited retinal… Read More »An analysis of the mutation spectrum for IRDs provides 20 further novel variants, including 6 variants showing pathogenic alterations.

SeaBeLife, a biotech company based in Roscoff, France, announce preliminary results on preclinical models for a new class of drugs for geographic atrophy (GA).  

SeaBeLife, a biotechnology company based in Roscoff, France, has announced in vivo clinical results for its SBL03 drug candidate, an ophthalmic gel aimed to combat… Read More »SeaBeLife, a biotech company based in Roscoff, France, announce preliminary results on preclinical models for a new class of drugs for geographic atrophy (GA).  

Real-world impacts of an observational study on X-linked retinitis pigmentosa (XLRP) patients’ experience, supported by the ERN-EYE Network.

Researchers at the Department of Translational Medicine, University of Ferrara, Italy, and colleagues in the ERN-EYE Network, have published paper on the first study to… Read More »Real-world impacts of an observational study on X-linked retinitis pigmentosa (XLRP) patients’ experience, supported by the ERN-EYE Network.

RhyGaze AG (Switzerland) receives $86M funding for optogenetic vision restoration, a spin-out of the Institute of Molecular and Clinical Ophthalmology, Basel. 

RhyGaze AG, based in Basel, Switzerland and Philadelphia, Pa., USA, have announced a Series A financing of USD $86 million for their company, aimed to… Read More »RhyGaze AG (Switzerland) receives $86M funding for optogenetic vision restoration, a spin-out of the Institute of Molecular and Clinical Ophthalmology, Basel.